JP6894380B2 - 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法 - Google Patents

治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法 Download PDF

Info

Publication number
JP6894380B2
JP6894380B2 JP2017556123A JP2017556123A JP6894380B2 JP 6894380 B2 JP6894380 B2 JP 6894380B2 JP 2017556123 A JP2017556123 A JP 2017556123A JP 2017556123 A JP2017556123 A JP 2017556123A JP 6894380 B2 JP6894380 B2 JP 6894380B2
Authority
JP
Japan
Prior art keywords
polynucleotide
til
tcr
cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017556123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520639A5 (https=
JP2018520639A (ja
Inventor
フランソワ ヴィニョー，
フランソワ ヴィニョー，
エードリアン ランガム ブリッグス，
エードリアン ランガム ブリッグス，
クリストファー ライアン クロウザー，
クリストファー ライアン クロウザー，
ステファン ジェイコブ ゴールドフレス，
ステファン ジェイコブ ゴールドフレス，
ソニア ティンブレイク，
ソニア ティンブレイク，
Original Assignee
アブビトロ， エルエルシー
アブビトロ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブビトロ， エルエルシー, アブビトロ， エルエルシー filed Critical アブビトロ， エルエルシー
Publication of JP2018520639A publication Critical patent/JP2018520639A/ja
Publication of JP2018520639A5 publication Critical patent/JP2018520639A5/ja
Priority to JP2021093583A priority Critical patent/JP2021129601A/ja
Application granted granted Critical
Publication of JP6894380B2 publication Critical patent/JP6894380B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/185—Nucleic acid dedicated to use as a hidden marker/bar code, e.g. inclusion of nucleic acids to mark art objects or animals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017556123A 2015-04-27 2016-04-27 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法 Expired - Fee Related JP6894380B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021093583A JP2021129601A (ja) 2015-04-27 2021-06-03 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153041P 2015-04-27 2015-04-27
US62/153,041 2015-04-27
PCT/US2016/029556 WO2016176322A1 (en) 2015-04-27 2016-04-27 Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021093583A Division JP2021129601A (ja) 2015-04-27 2021-06-03 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法

Publications (3)

Publication Number Publication Date
JP2018520639A JP2018520639A (ja) 2018-08-02
JP2018520639A5 JP2018520639A5 (https=) 2019-06-06
JP6894380B2 true JP6894380B2 (ja) 2021-06-30

Family

ID=57199815

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017556123A Expired - Fee Related JP6894380B2 (ja) 2015-04-27 2016-04-27 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法
JP2021093583A Pending JP2021129601A (ja) 2015-04-27 2021-06-03 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021093583A Pending JP2021129601A (ja) 2015-04-27 2021-06-03 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法

Country Status (9)

Country Link
US (2) US10982258B2 (https=)
EP (1) EP3289082A4 (https=)
JP (2) JP6894380B2 (https=)
CN (1) CN107849560B (https=)
AU (1) AU2016253964B2 (https=)
CA (1) CA2983937A1 (https=)
HK (1) HK1252248A1 (https=)
MX (1) MX2017013471A (https=)
WO (1) WO2016176322A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
JP6955487B2 (ja) 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
US11708574B2 (en) * 2016-06-10 2023-07-25 Myriad Women's Health, Inc. Nucleic acid sequencing adapters and uses thereof
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
KR102702552B1 (ko) 2016-12-23 2024-09-03 비스테라, 인크. 결합 폴리펩타이드 및 이의 제조 방법
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
EP4029939B1 (en) 2017-01-30 2023-06-28 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
KR102550778B1 (ko) 2017-05-26 2023-07-03 에이비비트로 엘엘씨 고-처리량 폴리뉴클레오타이드 라이브러리 시퀀싱 및 전사체 분석
EP3664835B1 (en) 2017-08-09 2024-10-23 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
WO2019084538A1 (en) * 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
SG11202007686VA (en) 2018-02-12 2020-09-29 10X Genomics Inc Methods characterizing multiple analytes from individual cells or cell populations
WO2019217758A1 (en) 2018-05-10 2019-11-14 10X Genomics, Inc. Methods and systems for molecular library generation
WO2019241249A1 (en) * 2018-06-11 2019-12-19 The Brigham And Women's Hospital, Inc. Single cell cloning approaches for biological studies
WO2019238939A1 (en) 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes
CN116298309B (zh) * 2018-08-13 2024-04-02 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
EP4219753A3 (en) * 2018-10-19 2023-09-06 Akoya Biosciences, Inc. Detection of co-occurring receptor-coding nucleic acid segments
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020206238A2 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
JP7725466B2 (ja) * 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ， インコーポレイテッド バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US12449419B1 (en) 2020-02-12 2025-10-21 10X Genomics, Inc. Methods for detecting binding of peptide-MHC monomers to T cells
CN111218502B (zh) * 2020-04-23 2020-07-21 圣湘生物科技股份有限公司 提升qPCR检测性能的组合物、反应液、用途及方法
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
WO2022081643A2 (en) * 2020-10-13 2022-04-21 10X Genomics, Inc. Compositions and methods for generating recombinant antigen binding molecules from single cells
CN114464253B (zh) * 2022-03-03 2023-03-10 予果生物科技（北京）有限公司 基于长读长测序进行实时病原检测的方法、系统和应用
EP4519675A4 (en) * 2022-05-03 2026-04-08 3T Biosciences Inc T-LYMPHOCYTE TARGET DISCOVERY
WO2024015862A1 (en) * 2022-07-13 2024-01-18 10X Genomics, Inc. Methods for characterization of antigen-binding molecules from biological samples
JP2026510460A (ja) 2023-03-13 2026-04-06 エイチ．リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択された腫瘍浸潤リンパ球の組成物ならびに関連するその生成及び使用方法
GB2629157A (en) * 2023-04-18 2024-10-23 The Institute Of Cancer Res Royal Cancer Hospital T cell receptor sequencing
WO2025080865A1 (en) 2023-10-11 2025-04-17 Turnstone Biologics Corp. Combination of tumor infiltrating lymphocytes (til) and low dose radiation
WO2025096638A2 (en) 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004648A1 (en) * 1988-10-20 1990-05-03 Alexander Alan Morley Method for diagnosis of monoclonality in leukaemia and lymphoma
WO2005059176A1 (en) * 2003-12-15 2005-06-30 Institut Pasteur Repertoire determination of a lymphocyte b population
US8268564B2 (en) * 2007-09-26 2012-09-18 President And Fellows Of Harvard College Methods and applications for stitched DNA barcodes
EP2364368B1 (en) * 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US10385391B2 (en) * 2009-09-22 2019-08-20 President And Fellows Of Harvard College Entangled mate sequencing
WO2012106385A2 (en) * 2011-01-31 2012-08-09 Apprise Bio, Inc. Methods of identifying multiple epitopes in cells
CN103732738A (zh) * 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
EP2861760B1 (en) 2012-06-15 2020-01-01 The Board of Regents of The University of Texas System High throughput sequencing of multiple transcripts of a single cell
JP6513035B2 (ja) * 2013-02-22 2019-05-15 アダプティヴ バイオテクノロジーズ コーポレーション 希少クロノタイプおよびその用途
KR20150132479A (ko) * 2013-03-15 2015-11-25 어댑티브 바이오테크놀로지스 코포레이션 복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
KR102758333B1 (ko) 2013-08-28 2025-01-23 벡톤 디킨슨 앤드 컴퍼니 대량의 동시 단일 세포 분석
CN113307880B (zh) * 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
EP3950944A1 (en) 2014-09-15 2022-02-09 AbVitro LLC High-throughput nucleotide library sequencing
EP3253479B1 (en) * 2015-02-04 2022-09-21 The Regents of The University of California Sequencing of nucleic acids via barcoding in discrete entities

Also Published As

Publication number Publication date
US20190024145A1 (en) 2019-01-24
HK1252248A1 (zh) 2019-05-24
US10982258B2 (en) 2021-04-20
MX2017013471A (es) 2018-08-01
WO2016176322A1 (en) 2016-11-03
JP2018520639A (ja) 2018-08-02
AU2016253964A1 (en) 2017-11-09
EP3289082A1 (en) 2018-03-07
US20210079454A1 (en) 2021-03-18
CA2983937A1 (en) 2016-11-03
EP3289082A4 (en) 2018-09-12
CN107849560A (zh) 2018-03-27
AU2016253964B2 (en) 2022-07-07
JP2021129601A (ja) 2021-09-09
CN107849560B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
JP6894380B2 (ja) 治療用薬剤および疾患特異的抗原をシーケンシング、判定、ペアリングおよび検証する方法
US20240052354A1 (en) Compositions and methods to treat cancer
US20210293812A1 (en) High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences
JP6869233B2 (ja) 親和性−オリゴヌクレオチドコンジュゲートおよびその使用
JP5498018B2 (ja) 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害
US11655303B2 (en) Anti-CD39 antibody compositions and methods
US12252746B2 (en) Anti-CD46 antibodies and methods of use
JP2023516388A (ja) 抗ｃｃｒ８剤
JP5719322B2 (ja) 腫瘍の治療
US20170269092A1 (en) Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
JP2018534927A (ja) Ｉｃｏｓ発現を決定する遺伝子シグネチャー
JP2017527313A (ja) ハイスループットヌクレオチドライブラリーシークエンシング
CN116997572A (zh) 小细胞肺癌的分类与治疗的方法和系统
AU2022270170A1 (en) Anti-il-27 antibodies and uses thereof
WO2025226603A1 (en) Methods for treating cancer using anti-ccr8 antibodies
CN118742322A (zh) 用于改变肿瘤微生物组的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210603

R150 Certificate of patent or registration of utility model

Ref document number: 6894380

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

LAPS Cancellation because of no payment of annual fees